{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["40(25)"],"submitter":["Provencio M"],"pubmed_abstract":["<h4>Purpose</h4>Neoadjuvant chemotherapy plus nivolumab has been shown to be effective in resectable non-small-cell lung cancer (NSCLC) in the NADIM trial (ClinicalTrials.gov identifier: NCT03081689). The 3-year overall survival (OS) and circulating tumor DNA (ctDNA) analysis have not been reported.<h4>Methods</h4>This was an open-label, multicenter, single-arm, phase II trial in which patients with stage IIIA NSCLC, who were deemed to be surgically resectable, were treated with neoadjuvant paclitaxel (200 mg/m<sup>2</sup> once a day) and carboplatin (area under curve 6) plus nivolumab (360 mg) once on day 1 of each 21-day cycle, for three cycles, followed by adjuvant nivolumab monotherapy for 1 year (240 mg once every 2 weeks for 4 months, followed by 480 mg once every 4 weeks for 8 month"],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pagination":["2924-2933"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9426809"],"repository":["biostudies-literature"],"pubmed_title":["Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)."],"pmcid":["PMC9426809"],"pubmed_authors":["Majem M","Massuti B","Casal Rubio J","Garcia-Garcia F","Martin-Lopez J","Bernabe Caro R","Sanchez-Herrero E","Garcia-Campelo MR","Provencio M","Lopez Vivanco G","Casarrubios M","Serna-Blasco R","Cobo M","Nadal E","Del Barco E","De Castro Carpeno J","Barneto Aranda I","Insa A","Martinez-Marti A","Pereira E","Viteri S","Rodriguez-Abreu D","Royuela A","Romero A","Calvo V","Franco F","Domine M","Vinolas N","Cruz-Bermudez A"],"additional_accession":[]},"is_claimable":false,"name":"Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial).","description":"<h4>Purpose</h4>Neoadjuvant chemotherapy plus nivolumab has been shown to be effective in resectable non-small-cell lung cancer (NSCLC) in the NADIM trial (ClinicalTrials.gov identifier: NCT03081689). The 3-year overall survival (OS) and circulating tumor DNA (ctDNA) analysis have not been reported.<h4>Methods</h4>This was an open-label, multicenter, single-arm, phase II trial in which patients with stage IIIA NSCLC, who were deemed to be surgically resectable, were treated with neoadjuvant paclitaxel (200 mg/m<sup>2</sup> once a day) and carboplatin (area under curve 6) plus nivolumab (360 mg) once on day 1 of each 21-day cycle, for three cycles, followed by adjuvant nivolumab monotherapy for 1 year (240 mg once every 2 weeks for 4 months, followed by 480 mg once every 4 weeks for 8 month","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2025-04-05T11:02:52.629Z","creation":"2025-02-19T02:49:09.283Z"},"accession":"S-EPMC9426809","cross_references":{"pubmed":["35576508"],"doi":["10.1200/JCO.21.02660"]}}